Top Industry Leaders in the Uterine Sarcoma Market
Pfizer announces positive preliminary data from a Phase 2 clinical trial of Talazoparib (BMN 189434) in combination with Pembrolizumab for treating advanced or recurrent leiomyosarcoma, a major type of uterine sarcoma.
Karyopharm Therapeutics receives FDA approval for Xpozio® (selinexor) for treating advanced or recurrent high-grade endometrial stromal sarcomas, another common subtype.
Merck KGaA releases promising early data from a Phase 1b/2a clinical trial of its investigational drug lenvatinib in combination with pembrolizumab for treating high-risk uterine sarcomas.
The Foundation for Sarcoma Research collaborates with pharmaceutical companies and academic institutions to fund clinical trials and accelerate development of new uterine sarcoma treatments.
The Society of Gynecologic Oncology (SGO) partners with patient advocacy groups to raise awareness of uterine sarcomas and improve access to quality care.
List of Uterine Sarcoma Key Companies in the Market
- Pfizer Inc. (U.S.)
- Intas Pharmaceuticals Ltd. (India)
- FMC Corporation (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Johnson & Johnson Services Inc. (U.S.)
- General Electric Company (U.S.)
- Koninklijke Philips N.V. (the Netherlands)
- Siemens Healthcare Private Limited (Germany)